Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands

Petra J Woestenberg*, Audrey J King, Birgit H B Van Benthem, Suzan Leussink, Marianne A B Van der Sande, Christian J P A Hoebe, Johannes A Bogaards, Medical Microbiological Laboratories and the Public Health Services

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Web of Science)


Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

Original languageEnglish
Pages (from-to)1280-1285
Number of pages6
JournalJournal of Infectious Diseases
Issue number8
Publication statusPublished - 15 Apr 2020


  • Human papillomavirus (HPV)
  • human papillomavirus vaccine
  • vaccine effectiveness
  • public health
  • anal cancer
  • RISK

Cite this